BRIEF published on 07/30/2026 at 21:35, 15 days 3 hours ago Poxel Records Positive Turnover amidst Financial Statement Postponement Financial Statements Royalties Poxel TWYMEEG® Sales Debt Valuation
BRIEF published on 07/30/2026 at 21:35, 15 days 3 hours ago Poxel: Q2 2026 Results and 2025 Financial Statements Report Revenue TWYMEEG® Poxel Sumitomo Pharma 2025 Accounts
PRESS RELEASE published on 07/30/2026 at 21:30, 15 days 3 hours ago Inside Information / Other news releases Poxel publishes Q2 2026 turnover & delays 2025 financial statements release. TWYMEEG(R) net sales up in Japan, reaching 2.9 billion yen; royalty rate to increase Financial Statements Turnover Royalties Poxel TWYMEEG
BRIEF published on 06/10/2026 at 20:18, 2 months 4 days ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 2 months 4 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 2 months 4 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 4 months 14 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
BRIEF published on 03/31/2026 at 13:12, 4 months 14 days ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
PRESS RELEASE published on 03/31/2026 at 13:07, 4 months 14 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Poxel announces sale of PXL770 for up to $196 million to SCYNEXIS. PXL770 targets ADPKD. Agreement includes upfront payment, development and commercial milestones. Phase 2 study planned for Q4 2026 Milestones Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/25/2026 at 22:03, 4 months 20 days ago Poxel Secures Additional Financing Through New Tranche D PDR Bonds Financing Continuation Plan Poxel IPF Partners Tranche D PDR
Published on 08/15/2026 at 00:15, 1 hour ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 1 hour 30 minutes ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:00, 2 hours 15 minutes ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/14/2026 at 16:05, 9 hours 10 minutes ago GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:02, 10 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/10/2026 at 18:00, 4 days 7 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 4 days 13 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 4 days 13 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 4 days 15 hours ago Number of shares and voting rights - July 2026 (In French only)
